Neovacs Advances Anti-TNF Immunotherapy In Crohn's Patients Who Failed Biologics
This article was originally published in The Pink Sheet Daily
Executive Summary
Completed Phase I/II trial offered the first indication of clinical benefit with an active immunotherapy against a cytokine, the French biotech's CEO says.